Ignite Creation Date:
2024-05-06 @ 2:11 PM
Last Modification Date:
2024-10-26 @ 1:27 PM
Study NCT ID:
NCT04249843
Status:
RECRUITING
Last Update Posted:
2024-01-05
First Post:
2020-01-21
Brief Title:
Study of Safety Pharmacokinetics and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
Sponsor:
MapKure LLC
Organization:
MapKure LLC
Study Overview
Official Title:
A First-in-Human Phase 1a1b Open Label Dose-Escalation and Expansion Study to Investigate the Safety Pharmacokinetics and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None